---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-114750"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T16:37:08.145346+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acrivon updates pipeline and AP3 data; cash runway into Q4 2024

## Summary
- Cash and marketable securities as of Dec 31, 2022 provide runway into at least Q4 2024.
- OncoSignature enriched ORR to 47% (NCI trial) and 58% (Lilly trial) vs 0% in non-responders.
- ACR-368 (CHK1/2) Phase 2 with registrational intent; new sensitive indications: endometrial and bladder cancer.
- WEE1 and PKMYT1 inhibitors expected to enter IND-enabling studies in 2023.
- Initial ACR-368 combination clinical readouts anticipated in H2 2023.

## SEC filing metadata
- accession: 0001193125-23-114750
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523114750/0001193125-23-114750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523114750/d482869d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-114750
- JSON: https://secwatch.observer/filing/0001193125-23-114750.json
- Plain text: https://secwatch.observer/filing/0001193125-23-114750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.